atezolizumab Durvalumab Durvalumab amfinzi)is a human immunoglobulin gi kappa)monoclonal antibody that blocks the interaction of programmed cell death ligand 1(PD-L1)with the PD-1 and CD80(B7.1)molecules.Durvalumab is approved for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: .have disease progression during or following platinum-containing chemotherapy. Ipilimumab Ipilimumab(Yervoy)is a human IgG1 antibody that binds the surface protein CTLA4.In normal physiology T receptor CD28 bnding to CaoorC prevenin RdDa6pmotei therefore negatively regulates the activation of T-c Active cytotoxic T-cells are required for the immune system to attack melanoma cells.Normally inhibited e an en ectoytoroxicTcs to increase te anti-um Regulatory T Nivolumab Ofatumumab Ofatumumab is Unlike rituximab,which binds to a large loop of the CD20 protein,ofatumumab binds to a separate,small loop This may explain their different characteristics.Compared to ritu pcndeatcotoictvyatalomcrdoewlGsmnmunogentaWohatumumabricscomolene Pembrolizumab Pembrolizumab is ap ved for the first-line treatment of patients with metastatic non-small cell lung cancer whose tumors have high PD-L1 expression as determined by an FDA-approved test. Rituximab CD20 is relatively unknown,CD20 may be a calcium channel involved in B-cell activation.The antibody's mode of action is prmarily through t induction OT ADC B-cells to ch Cytokine therapy
Cytokines ar proteins produced by many types of cells present within a tumor.they can modulate immune responses.The tumor often employs them to allow it to grow and reduce the immune response.These immune modulating effects allow them to be used as drugs to provoke an immune response.Two commonly used cytokines are interferons and interleukins. Interferon Interferons are produced by the immune system.They are usually involved in anti-viral response,but also have in three groups:type I(IFNa and IFNB),type II (IFNY)and type oma,cl ote anti-tumor immur yp :ha e been sho melanoma cancers.The most promising result was achieved in patients with stage 2 and 3 of ovarian carcinoma.The in vitro study of IFN-gamma in cancer cells is more extensive and results i ndicate ant IFN-gamma Interleukin Interleukins have an array of immune system effects.Interleukin-2 is used in the treatment of malignant cells,but its exact mechanism of action is unknown Combination immunotherapy CombnnaioscPDI and CTLA4inibitors can enhance anti-tmor response leading to durable response Combinatorial ablation and immunotherapy Combnnghrayofmhhances themming reponsendhas synergistic effects for curative metastatic cancer treatmen Polysaccharide-K Ministry of Heath,Labourand Welareappvhof polysaccharide-Kracted o ietary supplement in the US and Research Adoptive T-cell therapy Adoptive t-cell th fusion of T-cells(ado ransfer) thogens specifically the activate when the T-cell's surface receptors encounter cells that display parts of foreign proteins on their surface antigens.These can be either infected cells,or antigen presenting cells(APCs).They are found in normal tissue and in tumor tissue,where they are known as tumor infiltrating lymphocytes (TILs).They are activated by the